Nicole R. Hadas
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Nicole R. Hadas
Akebia Therapeutics, Inc. reported in an 8-K filed August 1, 2023 that Nicole R. Hadas was terminated as Senior Vice President, Chief Legal Officer and Corporate Secretary, effective October 6, 2023. The proxy statement of Akebia Therapeutics, Inc. reports total compensation of $1,046,304 for Nicole R. Hadas in fiscal 2023, including a base salary of $477,908. Disclosed compensation is on record for 3 fiscal years.
“In addition, on July 26, 2023, the Company and Ms. Hadas agreed to further extend the effective date of her termination to October 6, 2023, and, in the event of certain specified events, the effective date of her termination may extend to March 22, 2024 (the "Hadas July 2023 Amendment").”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Akebia Therapeutics, Inc. (AKBA)
Proxy statement
Start not stated–2024-04-25
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Akebia Therapeutics, Inc. (AKBA) | Senior Vice President, Chief Legal Officer | $477,908 | $1,046,304 |
| 2022 | Akebia Therapeutics, Inc. (AKBA) | Senior Vice President, Chief Legal Officer | $468,351 | $1,240,038 |
| 2021 | Akebia Therapeutics, Inc. (AKBA) | Senior Vice President, Chief Legal Officer | $448,747 | $1,230,453 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.